About Us

Making a Difference / Vision / News & Media

Making a difference, patient by patient

US WorldMeds is a specialty pharmaceutical company that develops, licenses, and brings to market unique healthcare products designed to improve the lives of patients with challenging conditions and unmet medical needs.

  • High-risk neuroblastoma
  • Malignant hyperthermia
  • Opioid withdrawal
  • Opioid overdose
  • And more

Patients are key to everything that we do at US WorldMeds

Vision


We will remain a sustainable, privately held specialty pharmaceutical company.

Mission


We will develop, license, and market meaningful and accessible healthcare products that improve lives and result in a thriving community of patients, employees, and shareholders.

Values


Make it happen
Agile approach
Generocity of spirit
Intuition and awareness
Confidence with humility

QUICK ACCESS TO THE LATEST COMPANY NEWS


Discover the latest news, featured stories, and past news from US WorldMeds

December 14, 2023

US WorldMeds Announces FDA Approval of IWILFIN™ (eflornithine) to Strengthen Fight Against Aggressive Childhood Cancer

First and only FDA-approved oral maintenance therapy for high-risk neuroblastoma

LOUISVILLE, Ky. December 14, 2023 -- USWM, LLC (US WorldMeds) today announced that the U.S. Food and Drug Administration (FDA) has approved IWILFIN™ (eflornithine) 192 mg tablets, a groundbreaking oral maintenance therapy for high-risk neuroblastoma. IWILFIN is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma who have demonstrated at least a partial response to prior multiagent, multimodality therapy, including anti-GD2 immunotherapy.

Read more
March 31, 2022

US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product

High-Dose Naloxone Now Available to Help Combat the Growing Epidemic of Overdose Deaths

LOUISVILLE, Ky. and SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- USWM, LLC (US WorldMeds), and Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the U.S. launch and availability of ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL. ZIMHI is a high-dose naloxone injection product FDA-approved for use in the treatment of opioid overdose as emergency therapy in settings where opioids may be present.

Read more

-News Archives (Click)-